Belantamab mafodotin
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab , and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity[1][2].
Product Specifications
CAS Number
2050232-20-5
Product Name Alternative
GSK2857916; Belantamab mafodotin-blm
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/belantamab-mafodotin.html
Purity
99.78
Solubility
10 mM in DMSO
Smiles
[Belantamabmafodotin]
Molecular Weight
149000 (average)
References & Citations
[1]Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21 (2) :207-221.|[2]Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80 (15) :1607-1613.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TL712386V 500 µL Each
Folh1 Rat shRNA Lentiviral Particle (Locus ID 85309)
Sign In for Pricing
View Details 
K4921206 1.0 µg DNA
Porcn sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 
GTR15339817 1 Vial
Lentiviral human ANXA8L1 shRNA (UAS) - Lentiviral human ANXA8L1 shRNA (UAS, GFP) plasmid
Sign In for Pricing
View Details